EIF2A and cancer: Current chemotherapeutic taxanes, such as paclitaxel, cabazitaxel, and docetaxel, target microtubules and activate the PERK-eIF2α axis, leading to cancer cell apoptosis in metastatic breast, ovarian, and lung cancers.